Karus is a research and development focused pharmaceutical company that is developing a new family of small-molecule drugs for the treatment of chronic human diseases such as cancer and inflammation.
The company's focus is the development of a new family of optimized, highly-potent and highly-selective histone deacetylase (HDAC) inhibitors (HDI's) which the company believes have the potential to become best-in-class treatments for cancer and inflammation.
Karus sits at the interface of innovative medicinal chemistry and unique insights in cancer-cell biology creating opportunities to design, optimize and develop new medicines.
Karus has established a strong and multi-disciplinary commercial and scientific team that is enabling the company to make rapid progress towards the clinic. The Company's lead programme is a synthetically optimised derivative of a clinically validated natural product with significantly improved potency, safety and dry-like properties.
Karus's unique approach to drug design has created new families of therapeutics that have blockbuster potential in major diseases such as cancer, inflammation and cardiovascular disease.![]()
Simon Kerry, Chief Executive Officer
Karus Therapeutics Ltd
John Fairclough Centre
University of Southampton
Highfield
Southampton
Hampshire SO17 1BJ
United Kingdom